US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ecopetrol SA

9.55

-0.5598-5.54%

Post-market: 9.620.0700+0.73%19:59 EDT

Volume:3.75M

Turnover:36.21M

Market Cap:19.63B

PE:5.80

High:9.87

Open:9.55

Low:9.48

Close:10.11

Loading ...

Overview Company News Filings

Shell's Brazil Subsidiary Joins Consortium Developing Gato do Mato Offshore Project

MT Newswires Live

Press Release: InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

EC World REIT Announces New Property Management Agreements

EC World Reit appoints new property managers, port operator

Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment

Simply Wall St.

Bristol Myers announces EC approval of Breyanzi

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS

Petrobras' Board Approves $283 Million Settlement Agreement

Pertamina Crude Oil Corruption: AGO Interrogates Four Officials

EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

Ecopetrol publishes draft chapter on social and environmental issues, including climate, for the year 2024

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Ecopetrol Unveils $2 Billion Debt Plan to Fund Inorganic Investments

Ecopetrol SA (EC) Q4 2024 Earnings Call Highlights: Record Production and Strategic Investments ...

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/EC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EC\",,,,,undefined,":{"symbol":"EC","market":"US","secType":"STK","nameCN":"Ecopetrol SA","latestPrice":9.55,"timestamp":1743710400000,"preClose":10.1098,"halted":0,"volume":3752354,"hourTrading":{"tag":"盘后","latestPrice":9.62,"preClose":9.55,"latestTime":"19:59 EDT","volume":5992,"amount":57328.3448,"timestamp":1743724754520},"delay":0,"floatShares":233421326,"shares":2055834734,"eps":1.647439,"marketStatus":"Not Yet Opened","change":-0.5598,"latestTime":"04-03 16:00:00 EDT","open":9.55,"high":9.866,"low":9.48,"amount":36209683.265732,"amplitude":0.038181,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.647439,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743753600000},"marketStatusCode":0,"adr":1,"adrRate":20,"listingDate":1221710400000,"exchange":"NYSE","adjPreClose":10.1098,"preHourTrading":{"tag":"盘前","latestPrice":9.6,"preClose":10.1098,"latestTime":"09:29 EDT","volume":10714,"amount":103965.81679,"timestamp":1743686999522},"postHourTrading":{"tag":"盘后","latestPrice":9.62,"preClose":9.55,"latestTime":"19:59 EDT","volume":5992,"amount":57328.3448,"timestamp":1743724754520},"volumeRatio":1.489952,"impliedVol":0.4514,"impliedVolPercentile":0.506},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EC\",,,,,undefined,":{"symbol":"EC","floatShares":233421326,"roa":"8.01%","roe":"18.41%","lyrEps":1.647439,"volumeRatio":1.489952,"shares":2055834734,"dividePrice":1.0404,"high":9.866,"amplitude":0.038181,"preClose":10.1098,"low":9.48,"week52Low":7.21,"pbRate":"0.97","psRate":"0.61","week52High":12.9,"institutionHeld":0,"latestPrice":9.55,"eps":1.647439,"divideRate":0.108942,"volume":3752354,"delay":0,"ttmEps":1.647439,"open":9.55,"prevYearClose":7.92,"prevWeekClose":10.22,"prevMonthClose":10.44,"prevQuarterClose":10.44,"fiveDayClose":10.39,"twentyDayClose":9.59,"sixtyDayClose":8.3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"EC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521815802","title":"Shell's Brazil Subsidiary Joins Consortium Developing Gato do Mato Offshore Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2521815802","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521815802?lang=en_us&edition=fundamental","pubTime":"2025-03-21 21:09","pubTimestamp":1742562591,"startTime":"0","endTime":"0","summary":"Shell  said Friday its Brasil subsidiary, Shell Brazil Petroleo, has joined a consortium holding stakes in the Gato do Mato deep-water project in the pre-salt area of the Santos Basin offshore of Brazil's Rio de Janeiro coast.Financial details of the investment in joining the consortium weren't disclosed.The Gato do Mato consortium now includes Shell, as operator of the project, with a 50% stake; Ecopetrol , with a 30% stake; TotalEnergies , with a 20% stake and the Brazil government's public company under its Ministry of Mines and Energy, Pre-Sal Petroleo, acting as the manager of the contract, Shell said.The project's recoverable resource volumes are estimated at about 370 million barrels. The project includes installation of a floating production storage and offloading vessel, and is designed to produce up to 120,000 barrels of oil per day once it is anticipated to begin operations in 2029, Shell said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2237443382.USD","LU2129689514.USD","SHEL","LU1162221912.USD","LU2237443549.SGD","EC","TTE","BK4561","LU2129689605.HKD","BK4585","LU0300736062.USD","LU2236285917.USD","LU0300736492.USD","LU2237443895.HKD","LU0098860793.USD","BK4588","LU2237443465.HKD","LU0278409577.USD","LU0320765646.SGD","LU2237443978.SGD","BK4201","LU2237443622.USD","LU2129689431.USD"],"gpt_icon":1},{"id":"2520458334","title":"Press Release: InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2520458334","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520458334?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:30","pubTimestamp":1742470200,"startTime":"0","endTime":"0","summary":"-- Received European Commission approval for GOHIBIC  for. the treatment of SARS-CoV-2-induced acute respiratory distress syndrome. pyoderma gangrenosum  to enable an expected interim analysis for. trial size adaptation or futility by the end of May 2025. -- Dosed first patient in Phase 2a trial for oral C5aR inhibitor, INF904,INF904 in CSU and HS -- Topline Phase 2a data expected in summer 2025. In December 2024, InflaRx announced that the first patient had been dosed in its Phase 2a basket study with INF904 in CSU and HS. This is a multi-center, open-label study evaluating multiple INF904 dosing regimens over 4 weeks of treatment in a total of 75 patients . The goal of the trial is to generate additional safety and pharmacokinetic  data and to provide signs of clinical benefit. After the 4-week treatment period, patients will be follow","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4567","LU1430594728.SGD","LU1868836757.USD","EC","LU1914381329.SGD","LU0640476718.USD","IE00B3T34201.USD","LU0234572021.USD","LU0237698245.USD","BK4022","IFRX","IE00B1XK9C88.USD","LU0098860793.USD","LU0320765646.SGD","IE00BLSP4452.SGD","LU1162221912.USD","LU1868837300.USD","LU2552382132.HKD","R","LU1585245621.USD","SG9999002232.USD","LU2129689431.USD","ARDS","LU0689626769.HKD","LU1929549753.HKD","BK4585","LU0061475181.USD","BK4181","BK4201","BK4139","BK4018","LU0868494617.USD","BK4218","LU0094547139.USD","BK4559","PK","SG9999002224.SGD","BK4588","IE000M9KFDE8.USD","LU2242652126.USD","IE00BWXC8680.SGD","LU0323591593.USD","LU0124676726.USD","LU1868837136.USD","LU0096364046.USD","SG9999015341.SGD","LU0234570918.USD","SG9999014567.USD","PG"],"gpt_icon":0},{"id":"2520193740","title":"Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2520193740","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520193740?lang=en_us&edition=fundamental","pubTime":"2025-03-20 04:01","pubTimestamp":1742414460,"startTime":"0","endTime":"0","summary":"BOSTON, March 19, 2025  -- Rhythm Pharmaceuticals, Inc. , a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare  for setmelanotide as a treatment for acquired hypothalamic obesity.Setmelanotide is a melanocortin-4 receptor  agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic obesity, with topline data on track to be disclosed in the second quarter of 2025.In Japan, drugs can be designated as orphan drugs if they treat diseases affecting fewer than 50,000 patients in Japan and there is a high medical need.Rhythm estimates there are 5,000 to 8,000 people living with acquired hypothalamic obesity in Japan, 5,000 to 10,000 people living with acquired hypothalamic obesity in the U.S., and 3,500 to 10,00","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-orphan-drug-200100660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4201","RYTM","BK4139","BK4585","EC"],"gpt_icon":0},{"id":"2520053342","title":"EC World REIT Announces New Property Management Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2520053342","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520053342?lang=en_us&edition=fundamental","pubTime":"2025-03-17 08:12","pubTimestamp":1742170330,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EC World Real Estate Investment Trust ( ($SG:BWCU) ). EC World Real Estate Investment Trust has announced new p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ec-world-reit-announces-new-property-management-agreements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ec-world-reit-announces-new-property-management-agreements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ECWDF","BK4209","SG","BK4224","BK4201","EC","REIT"],"gpt_icon":0},{"id":"2520555574","title":"EC World Reit appoints new property managers, port operator","url":"https://stock-news.laohu8.com/highlight/detail?id=2520555574","media":"businesstimes","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520555574?lang=en_us&edition=fundamental","pubTime":"2025-03-17 01:50","pubTimestamp":1742147441,"startTime":"0","endTime":"0","summary":"The contract terms for the appointments are for one year ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"bustime_highlight","url":"https://www.businesstimes.com.sg/companies-markets/ec-world-reit-appoints-new-property-managers-port-operator","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businesstimes.com.sg/companies-markets/ec-world-reit-appoints-new-property-managers-port-operator","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bustime_highlight","symbols":["EC","BK4201","CFA.SI"],"gpt_icon":0},{"id":"2519338297","title":"Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2519338297","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519338297?lang=en_us&edition=fundamental","pubTime":"2025-03-15 01:27","pubTimestamp":1741973244,"startTime":"0","endTime":"0","summary":"Bristol-Myers Squibb recently gained European Commission approval for Breyanzi, broadening treatment options for indolent non-Hodgkin lymphoma, which was a significant recent event. During the last quarter, the company's stock rose by 8%, amid a backdrop of several key events and broader market trends. Positive results from the Phase 3 POETYK PsA-2 trial for Sotyktu and a substantial share buyback program may have bolstered investor confidence. Additionally, a quarterly dividend declaration continued to assure income-oriented investors. On a broader scale, market activity demonstrated volatility; however, the technology sector experienced a rally, and the Dow Jones Industrial Average rebounded, signaling a partial market recovery following a correction phase. These factors contributed to Bristol-Myers Squibb's share performance, as the company navigated a challenging but promising landscape with strategic product approvals and shareholder-focused actions.Gain insight into the risks fac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-nyse-bmy-172724887.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU0321505439.SGD","LU1430594728.SGD","IE0002141913.USD","LU0225284248.USD","LU1868836591.USD","IE00BJJMRZ35.SGD","LU0114720955.EUR","LU0985481810.HKD","IE00BFXG1179.USD","EC","LU2125154778.USD","LU1032466523.USD","LU1868837136.USD","LU1670711040.USD","LU0456855351.SGD","LU1291159041.SGD","LU1585245621.USD","BK4581","LU2242646821.SGD","NYSE","IE00BJT1NW94.SGD","LU1868837300.USD","BK4534","BK4588","LU2242652126.USD","BMY","LU2125154935.USD","IE00B2B36J28.USD","LU0882574055.USD","LU1670710588.SGD","LU0096364046.USD","IE00BSNM7G36.USD","BK4585","LU2360032135.SGD","LU1868836757.USD","LU1323610961.USD","IE00BFTCPJ56.SGD","BK4559","LU1093756168.USD","BK4007","LU0306806265.USD","LU0306807586.USD","BK4201","LU0868494617.USD","LU0061475181.USD","LU0237698245.USD","LU1261432733.SGD","LU1670711123.USD","LU2133065610.SGD"],"gpt_icon":0},{"id":"2519872049","title":"Bristol Myers announces EC approval of Breyanzi","url":"https://stock-news.laohu8.com/highlight/detail?id=2519872049","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519872049?lang=en_us&edition=fundamental","pubTime":"2025-03-14 19:06","pubTimestamp":1741950373,"startTime":"0","endTime":"0","summary":"Bristol Myers (BMY) Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T cel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bristol-myers-announces-ec-approval-of-breyanzi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bristol-myers-announces-ec-approval-of-breyanzi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4559","BK4534","LU1585245621.USD","LU2125154935.USD","LU0321505868.SGD","IE00BJJMRZ35.SGD","LU0306806265.USD","LU0321505439.SGD","LU2242646821.SGD","BK4588","LU1718418525.SGD","BK4201","BK4585","IE00BFXG1179.USD","LU1571399168.USD","LU1868837300.USD","IE0002141913.USD","LU1868836914.USD","LU2242652126.USD","LU1868836591.USD","MYE","LU1093756168.USD","LU2125154778.USD","BK4532","LU1074936037.SGD","IE00B2B36J28.USD","LU0306807586.USD","LU1670711123.USD","LU0225771236.USD","LU1868836757.USD","LU1291159041.SGD","LU1261432733.SGD","LU1093756325.SGD","BK4126","LU1868837136.USD","LU0985481810.HKD","EC","LU2133065610.SGD","LU0868494617.USD","LU1670710588.SGD","LU0882574055.USD","BMY","BK4581","IE00BSNM7G36.USD","LU0114720955.EUR","LU1670710661.SGD","LU1670711040.USD","LU2360032135.SGD","LU1323610961.USD","LU0237698245.USD"],"gpt_icon":0},{"id":"2519808851","title":"Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2519808851","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519808851?lang=en_us&edition=fundamental","pubTime":"2025-03-14 18:59","pubTimestamp":1741949940,"startTime":"0","endTime":"0","summary":"In the TRANSCEND FL trial, 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving complete response*. Breyanzi demonstrated sustained clinical benefit, with 75.7% of patients still in response at 18 months, and a consistent safety profile with no new safety signals observed. PRINCETON, N.J., March 14, 2025----Bristol Myers Squibb  today announced that the European Commission  has granted approval to Breyanzi , a CD19-directed chimeric antigen receptor  T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma  after two or more lines of systemic therapy.This expanded approval is applicable to all European Union  member states as well as the European Economic Area  countries Iceland, Norway and Liechtenstein.** Breyanzi is also approved in the EU for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma , high grade B-cell lymphoma , primary mediastinal large B-cell lymphoma  and FL grade 3B","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-approval-105900919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAR","LU1430594728.SGD","EC","LU0237698245.USD","LU1323610961.USD","BK4534","LU1032466523.USD","LU1261432733.SGD","LU2125154778.USD","IE00BJJMRZ35.SGD","LU1585245621.USD","IE0031619046.USD","MYE","BMY","IE00B66KJ199.SGD","BK4528","LU2360032135.SGD","LU2065731478.USD","BK4585","IE00BSNM7G36.USD","LU0061475181.USD","LU0456855351.SGD","BK4205","LU0882574055.USD","LU1718418525.SGD","BK4201","HSCT","LU0868494617.USD","LU0225771236.USD","LU2125154935.USD","LU0306806265.USD","BK4230","LU2133065610.SGD","BK4588","BK4156","FL","IE00BFTCPJ56.SGD","LU1093756325.SGD","LU2242652126.USD","CR","LU2242646821.SGD","LU1670711040.USD","EEA","IE00BFXG1179.USD","LU0114720955.EUR","LU0096364046.USD","BK4094","UK","CRS"],"gpt_icon":0},{"id":"2519389886","title":"Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519389886","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519389886?lang=en_us&edition=fundamental","pubTime":"2025-03-14 06:07","pubTimestamp":1741903620,"startTime":"0","endTime":"0","summary":"○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/13/3042670/0/en/Cellectis-Reports-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2024-and-Provides-a-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4080","BK4139","BK4183","BK4231","EC","ODD","CAR","CLLS","SITC","RCC","BK4022","BK4230","BK4201"],"gpt_icon":0},{"id":"2519007017","title":"Rxulti® (brexpiprazole) approved in the European Union for the treatment of schizophrenia in adolescents aged 13 years and older","url":"https://stock-news.laohu8.com/highlight/detail?id=2519007017","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519007017?lang=en_us&edition=fundamental","pubTime":"2025-03-13 16:45","pubTimestamp":1741855500,"startTime":"0","endTime":"0","summary":"Brexpiprazole's indication for the treatment of schizophrenia in adults is extended to include adolescents aged 13 years and older1. Approval follows a positive Committee for Medicinal Products for Human Use  opinion from the European Medicines Agency in January 20252. Treatment with brexpiprazole  significantly reduced the symptoms of schizophrenia as measured by PANSS total score compared to placebo3. WINDSOR, England and VALBY, Denmark, March 13, 2025 /PRNewswire/ --Otsuka Pharmaceutical Europe Ltd.  and H. Lundbeck A/S  today announced that the European Commission  has approved Rxulti for the treatment of schizophrenia in adolescents aged 13 years and older.1 Brexpiprazolewas previously approved in the European Union in 2018 for the treatment of schizophrenia in adults.4. Brexpiprazole was discovered by Otsuka and is being co-developed and co-commercialised under a collaboration and license agreement between Otsuka Pharmaceutical Europe Ltd. a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rxulti-brexpiprazole-approved-european-union-084500819.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rxulti-brexpiprazole-approved-european-union-084500819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EC","CHMP","HLUBF","BK4087","BK4201","HLBBF","BK4007"],"gpt_icon":0},{"id":"2518570777","title":"Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS","url":"https://stock-news.laohu8.com/highlight/detail?id=2518570777","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518570777?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:30","pubTimestamp":1741725000,"startTime":"0","endTime":"0","summary":"RYTELO is the first and only telomerase inhibitor approved in the U.S. and Europe. FOSTER CITY, Calif., March 11, 2025----Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the European Commission  has granted marketing authorization for RYTELO  as a monotherapy for the treatment of adult patients with transfusion-dependent  anemia due to very low, low or intermediate risk myelodysplastic syndromes  without an isolated deletion 5q cytogenetic  abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy . Lower-risk MDS is a progressive blood cancer with high unmet need, where many patients with anemia become dependent on red blood cell transfusions, which can be associated with clinical consequences and decreased quality of life.The marketing authorization of RYTELO approved by the EC is supported by data from the IMerge Phase 3 clinical trial, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geron-announces-european-commission-approval-203000014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4201","GERN","TD","BK4079","BK4139","COMP","EC","BK4566","BK4585","BK4207","BK4006","BK4539","RS"],"gpt_icon":0},{"id":"2518747046","title":"Petrobras' Board Approves $283 Million Settlement Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2518747046","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518747046?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:23","pubTimestamp":1741695780,"startTime":"0","endTime":"0","summary":"Petrobras PBR, Brazil’s state-run oil and gas company, has announced that its board has approved an agreement to settle a longstanding legal dispute with EIG Energy Fund XIV in a U.S. court. As part of this agreement, the Brazilian company will make a $283 million payment to resolve the issue. This decision marks a significant development for Petrobras as it addresses legal matters related to past investments.In a securities filing, the integrated oil and gas company confirmed that this contingency has been provisioned in its earnings. This ensures that the company is prepared for the financial implications of the settlement. By making this payment, PBR aims to resolve the issue efficiently, allowing it to focus on the ongoing operations without further legal distractions.Last year, PBR disclosed that it made two significant gas discoveries in the Guajira offshore basin in Colombia, which dramatically raised the gas potential in the region to an estimate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/petrobras-board-approves-283-million-122300320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0572108347.SGD","EC","LU0072463663.USD","LU1515016050.SGD","LU1883866441.USD","LU0256859116.SGD","LU0106259046.USD","BK4548","LU2462611646.USD","BK4585","AR","BK4213","LU1051769294.HKD","LU0788109048.HKD","LU1051768304.USD","BK4588","LU0651947912.USD","BK4179","LU2498475776.HKD","AROC","BK4201","LU0651946864.USD","IE00B1B80R65.USD","LU0265266980.USD","PBR"],"gpt_icon":0},{"id":"2518710850","title":"Pertamina Crude Oil Corruption: AGO Interrogates Four Officials","url":"https://stock-news.laohu8.com/highlight/detail?id=2518710850","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518710850?lang=en_us&edition=fundamental","pubTime":"2025-03-11 07:15","pubTimestamp":1741648547,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta - The Attorney General's Office  continues to develop the alleged corruption case in the management of crude oil and refinery products at PT Pertamina by interrogating four PT Pertamina officials on Monday, March 10, 2025. The four witnesses questioned by investigators are MM as Manager Quality System & Knowledge Management PT Kilang Minyak Internasional, IPG as VP PSO Management at the Finance Directorate of PT Pertamina, AEU as Manager Contract & Settlement PT Pertamina Patra Niaga, and VY as Senior Expert Trader at the Marketing Directorate of PT Pertamina Patra Niaga for the period of 2021-2023.\"The examination of witnesses is carried out to strengthen evidence and complete the case files in the said case,\" said Head of the Legal Information Center of AGO Harli Siregar in his official statement on Monday, March 10, 2025.","market":"other","thumbnail":"https://statik.tempo.co/data/2025/01/14/id_1369244/1369244_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/01/14/id_1369244/1369244_720.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/1984933/pertamina-crude-oil-corruption-ago-interrogates-four-officials","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK4201","SDS","BK4585","BK4006","BK4588","RS","AP","BK4166","PT","EC","AGO","BK4107"],"gpt_icon":0},{"id":"2518277677","title":"EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277677","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518277677?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:41","pubTimestamp":1741614060,"startTime":"0","endTime":"0","summary":"Bristol Myers BMY announced that the European Commission  has approved the blockbuster immuno-oncology drug Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma , a type of liver cancer.This approval is based on results of phase III CheckMate -9DW clinical study demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of Lenvima  or Nexavar .HCC accounts for 90% of liver cancer cases worldwide, which is the third most frequent cause of cancer death.In August 2024, the FDA also accepted BMY’s supplemental biologics license application  for Opdivo plus Yervoy as a potential first-line treatment option for adult patients with unresectable HCC and assigned a target action date of April 21, 2025.We note that the FDA granted accelerated approval in 2020 for the combination of Opdivo plus Yervoy as a second-line treatment fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ec-approves-bristol-myers-opdivo-134100082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","EC","BK4007","BK4532","GILD","LU2360032135.SGD","LU0306807586.USD","LU1074936037.SGD","LU1670710661.SGD","LU0109394709.USD","LU0321505439.SGD","LU1670710588.SGD","BK4566","LU0985481810.HKD","LU0882574055.USD","LU1093756168.USD","BMY","BK4126","LU0889565916.HKD","LU0289739699.SGD","BK4559","LU1032466523.USD","LU1261432733.SGD","IE00BZ1G4Q59.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU0225771236.USD","LU1430594728.SGD","LU2125154778.USD","LU1868837136.USD","BK4578","HCC","MYE","LU2089984988.USD","IE0009355771.USD","LU0320765992.SGD","LU1868837300.USD","LU1868836914.USD","BK4139","LU0306806265.USD","LU1323610961.USD","BMRN","LU1093756325.SGD","IE00BSNM7G36.USD","LU2242646821.SGD","LU0321505868.SGD","IE00B2B36J28.USD","LU0237698245.USD","LU0061475181.USD","BK4568"],"gpt_icon":0},{"id":"2518240670","title":"WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2518240670","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518240670?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:00","pubTimestamp":1741604400,"startTime":"0","endTime":"0","summary":"– Second major approval for WAINZUA, which is marketed in the U.S. as WAINUA –。– EU approval based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo –。CARLSBAD, Calif., March 10, 2025----Ionis Pharmaceuticals, Inc.  announced today that Ionis and AstraZeneca’s WAINZUA  has been approved in the European Union  for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector.ATTR is caused by the accumulation of liver-derived misfolded TTR protein i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wainzua-eplontersen-approved-eu-treatment-110000305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IONS","BK4201","CHMP","BK4207","BK4087","PN","CM","BK4156","EC"],"gpt_icon":0},{"id":"2517430281","title":"Ecopetrol publishes draft chapter on social and environmental issues, including climate, for the year 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517430281","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517430281?lang=en_us&edition=fundamental","pubTime":"2025-03-07 22:06","pubTimestamp":1741356360,"startTime":"0","endTime":"0","summary":"BOGOTA, Colombia, March 7, 2025 /PRNewswire/ -- Ecopetrol S.A.  announces that, in accordance with External Circular 031 of 2021 issued by the Superintendency of Finance of Colombia, it haspublished the draft chapter on practices, policies, processes and indicators related to socialand environmental issues, including climate, which can be consulted in Spanish on Ecopetrol's website.Ecopetrol is the largest company in Colombia and one of the main integrated energy companies in the American continent, with more than 19,000 employees. In Colombia, it is responsible for more than 60% of the hydrocarbon production of most transportation, logistics, and hydrocarbon refining systems, and it holds leading positions in the petrochemicals and gas distribution segments. With the acquisition of 51.4% of ISA's shares, the company participates in energy transmission, the management of real-time systems , and the Barranquilla - Cartagena coastal highway concession. At the international level, Ecopetr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ecopetrol-publishes-draft-chapter-social-140600444.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ecopetrol-publishes-draft-chapter-social-140600444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EC","BK4201"],"gpt_icon":0},{"id":"2517828574","title":"TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517828574","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517828574?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:30","pubTimestamp":1741350600,"startTime":"0","endTime":"0","summary":"NEW YORK, March  07, 2025  (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI (ublituximab-xiiy) data in patients wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038884/8790/en/TG-Therapeutics-Announces-Schedule-of-Data-Presentations-for-BRIUMVI-ublituximab-in-Multiple-Sclerosis-at-the-American-Academy-of-Neurology-2025-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","BK4090","TG","BK4153","LU0006306889.USD","LU0106831901.USD","LU0267386448.USD","LU0314104364.USD","LU2089284900.SGD","LU1720051108.HKD","LU0225283273.USD","LU0158827948.USD","LU0158827781.USD","BK4504","LU1989772840.SGD","LU0971096721.USD","EC","TGTX","LU2089283258.USD","LU2347655156.SGD","IE00BKVL7J92.USD","BK4139","BK4107","LU0106261372.USD","LU1989772923.USD","LU1363072403.SGD","BK4127","BK4534","BK4588","LU2023251221.USD","LU1548497426.USD","LU1732800096.USD","LU2111349929.HKD","BK4585","LU1668664300.SGD","LU1074936037.SGD","LU2028103732.USD","LU1162221912.USD","BK4117","LU0912757837.SGD","LU1720051017.SGD","AFG","IE00BZ1G4Q59.USD","BK4135","LU2357305700.SGD","BK4516","CNS","LU2133065610.SGD","PML","LU0098860793.USD"],"gpt_icon":0},{"id":"2517438854","title":"Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438854","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438854?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:59","pubTimestamp":1741348740,"startTime":"0","endTime":"0","summary":"Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib. PRINCETON, N.J., March 07, 2025----Bristol Myers Squibb  today announced that the European Commission  has approved Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma .\"The European Commission’s approval for Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that may extend survival for patients with hepatocellular carcinoma,\" said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. \"This approval marks a critical milestone in our commitment to improving outcomes for patients with liver cancer. We look forward to bringing this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-115900243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505868.SGD","BK4532","LU0321505439.SGD","BK4213","BK4097","LU1430594728.SGD","LU0225284248.USD","LU1868836914.USD","MYE","LU1868836591.USD","LU0114720955.EUR","ORR","VOD","EC","RCC","LU1032466523.USD","LU1868837136.USD","LU1670711040.USD","LU1291159041.SGD","LU2242646821.SGD","BK4581","HSCT","LU1868837300.USD","CRC","HCC","TEN","BMY","OS","LU2125154935.USD","BK4132","LU1670710588.SGD","LU0096364046.USD","IE00BSNM7G36.USD","AEIS","BK4124","IE00B19Z4B17.USD","IE00BFTCPJ56.SGD","CRT","IE00B7SZL793.SGD","LU0306806265.USD","LU0306807586.USD","ALK","BK4201","LU0868494617.USD","LU0061475181.USD","LU0237698245.USD","LU1261432733.SGD","BK4157","LU1571399168.USD"],"gpt_icon":0},{"id":"2517558194","title":"Ecopetrol Unveils $2 Billion Debt Plan to Fund Inorganic Investments","url":"https://stock-news.laohu8.com/highlight/detail?id=2517558194","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517558194?lang=en_us&edition=fundamental","pubTime":"2025-03-07 01:49","pubTimestamp":1741283340,"startTime":"0","endTime":"0","summary":"Ecopetrol S.A.EC, the Colombian majority state-owned energy firm, has announced plans to take on $2 billion of additional debt this year to finance inorganic investments. The company is exploring options to seek funding through banks and capital markets. Its board has approved the additional debt funding, which includes $1 billion in structural debt. Further, $1 billion has been authorizedas a temporary measure, as mentioned by a company spokesperson.The debt would be used for inorganic projects, such as the acquisition of new assets or starting over new ventures. EC’s VP of Finance, Camilo Barco, mentioned that the investment plan is anticipated to pick up pace in the second half of the year.The Colombian energy company has outlined an investment plan ranging between $5.9 billion and $6.8 billion for 2025. A major portion of this investment is expected to come from its own cash reserves, which totaled $4.4 billion at the end of 2024. In 2024, EC reported an average production of745,80","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ecopetrol-unveils-2-billion-debt-174900540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B29SXL02.USD","AROC","LU0170899867.USD","EC","BK4179","LU2449327464.USD","LU0368265418.SGD","LU0053671581.USD","LU0788109394.HKD","BK4144","LU0251131958.USD","LU0048573561.USD","LU0314104364.USD","LU0345770308.USD","LU0345781412.USD","LU0345780950.USD","LU0630314457.HKD","IE00B29SXK94.USD","LU0345770993.USD","BK4201","LU0742534661.SGD","BK4213","LU0251142724.SGD","MTDR","LU0122376428.USD","CQP","LNG"],"gpt_icon":0},{"id":"2517840521","title":"Ecopetrol SA (EC) Q4 2024 Earnings Call Highlights: Record Production and Strategic Investments ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2517840521","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517840521?lang=en_us&edition=fundamental","pubTime":"2025-03-06 15:08","pubTimestamp":1741244898,"startTime":"0","endTime":"0","summary":"EBITDA: COP54.1 trillion with an EBITDA margin of 41%.Net Income: COP14.9 trillion, excluding external factors would be COP21 trillion.Reserve Replacement Ratio: 104% with 260 million barrels of oil equivalent added.Average Production: 746,000 barrels of oil equivalent per day.CapEx: Over $6 billion, including the acquisition of CPO-09.Operational Availability: 94.5% with a throughput of 414,000 barrels per day.Gross Refining Margin: $9.9 per barrel, a decrease of $10 compared to 2023.Free Cash Flow: Highest in history, supported by operational performance and receivables collection.Debt to EBITDA Ratio: 2.2x with an average debt life of 9.3 years.Investment Plan for 2025: COP24 trillion to COP28 trillion, with 60% for energy security and 40% for energy transition.GuruFocus has detected 6 Warning Signs with EC.Ecopetrol SA  faced electrical reliability challenges in its downstream operations, affecting operational availability.A: Camilo Barco, CFO, explained that the impairment shown i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ecopetrol-sa-ec-q4-2024-070818140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EC"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EC\",params:#limit:5,,,undefined,":[{"date":"2025-06-26","symbol":"EC","amount":0.5202,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-26","defaultRemindTime":1750944600000,"name":"哥伦比亚国家石油","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-07","payableDate":"2025-06-26","currency":"USD","dateTimestamp":1750910400000,"payDate":"2025-07-07"},{"date":"2025-04-03","symbol":"EC","amount":0.5202,"announcedDate":"2025-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-03","defaultRemindTime":1743687000000,"name":"哥伦比亚国家石油","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-11","payableDate":"2025-04-03","currency":"USD","dateTimestamp":1743652800000,"payDate":"2025-04-11"},{"market":"US","date":"2025-03-04","symbol":"EC","fiscalQuarterEnding":"2024/12","expectedEps":0.36,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1741064400000,"reportTimeType":"post","actualEps":0.74},{"market":"US","date":"2024-11-13","symbol":"EC","fiscalQuarterEnding":"2024/09","expectedEps":0.46,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":0.61},{"market":"US","date":"2024-08-13","symbol":"EC","fiscalQuarterEnding":"2024/06","expectedEps":0.57,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"post","actualEps":0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EC\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-17","recordDate":"2015-06-19","paymentDate":"2015-06-30","value":1.0397119,"currency":"USD"},{"executeDate":"2017-04-25","recordDate":"2017-04-27","paymentDate":"2017-05-08","value":0.160581,"currency":"USD"},{"executeDate":"2018-04-17","recordDate":"2018-04-18","paymentDate":"2018-04-27","value":0.605505,"currency":"USD"},{"executeDate":"2019-04-23","recordDate":"2019-04-24","paymentDate":"2019-05-03","value":1.0849538,"currency":"USD"},{"executeDate":"2019-12-26","recordDate":"2019-12-27","paymentDate":"2020-01-02","value":0.4861737,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0909,"buy":0,"hold":0.5455,"sell":0.2727,"strongSell":0.0909,"meanLabel":"HOLD","meanPercent":0.5455,"analysts":11,"updateTime":1739851200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/EC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"EC","date":"2025-04-02","current":5.740208,"percent":0.535772,"low":2.588919,"twenty":3.863076,"median":5.451025,"eighty":12.825744,"high":64.266012,"avg":9.872976,"sd":11.437009,"marketCap":20657921498.99},"quantilePoints":[{"date":"2020-04-09","current":7.060195,"twenty":-8.145361,"median":10.488174,"eighty":13.847901,"marketCap":25102286700.23},{"date":"2020-04-17","current":5.833636,"twenty":-8.145361,"median":10.484881,"eighty":13.847901,"marketCap":20130951753.92},{"date":"2020-04-24","current":5.713971,"twenty":-8.115955,"median":10.451604,"eighty":13.826153,"marketCap":19439795746.79},{"date":"2020-05-01","current":6.252461,"twenty":-8.115955,"median":10.432105,"eighty":13.778662,"marketCap":21690070900.86},{"date":"2020-05-08","current":6.102881,"twenty":-8.115955,"median":10.415218,"eighty":13.778662,"marketCap":21658246531.61},{"date":"2020-05-15","current":7.128331,"twenty":-8.115955,"median":10.390367,"eighty":13.778662,"marketCap":20193195773.75},{"date":"2020-05-22","current":7.276069,"twenty":-8.115955,"median":10.372727,"eighty":13.733732,"marketCap":21421174870.89},{"date":"2020-05-29","current":7.349937,"twenty":-8.115955,"median":10.362824,"eighty":13.714284,"marketCap":22056885495.23},{"date":"2020-06-05","current":8.661107,"twenty":-8.115955,"median":10.344145,"eighty":13.709422,"marketCap":27085411834.39},{"date":"2020-06-12","current":7.848551,"twenty":-8.115955,"median":10.319805,"eighty":13.699296,"marketCap":23200471645.31},{"date":"2020-06-19","current":7.903953,"twenty":-8.092431,"median":10.300132,"eighty":13.688426,"marketCap":23609994267.63},{"date":"2020-06-26","current":7.645412,"twenty":-8.08655,"median":10.287946,"eighty":13.686342,"marketCap":22623417242.58},{"date":"2020-07-02","current":7.682347,"twenty":-8.08655,"median":10.273776,"eighty":13.686342,"marketCap":23374528521.7},{"date":"2020-07-10","current":7.682347,"twenty":-8.08655,"median":10.231601,"eighty":13.672495,"marketCap":23632243210.7},{"date":"2020-07-17","current":8.199428,"twenty":-8.08655,"median":10.199864,"eighty":13.663263,"marketCap":25086314025.12},{"date":"2020-07-24","current":8.199428,"twenty":-8.068906,"median":10.178679,"eighty":13.650092,"marketCap":24734192014.9},{"date":"2020-07-31","current":7.682347,"twenty":-8.057144,"median":10.111782,"eighty":13.640634,"marketCap":22930803559.42},{"date":"2020-08-07","current":11.632318,"twenty":-8.057144,"median":10.172576,"eighty":13.640183,"marketCap":23832899932.5},{"date":"2020-08-14","current":11.793133,"twenty":-8.057144,"median":10.192421,"eighty":13.629769,"marketCap":23903159981.5},{"date":"2020-08-21","current":11.685923,"twenty":-8.057144,"median":10.231601,"eighty":13.619393,"marketCap":23443635095.52},{"date":"2020-08-28","current":11.65912,"twenty":-8.057144,"median":10.270329,"eighty":13.617103,"marketCap":23779198827.58},{"date":"2020-09-04","current":11.498305,"twenty":-8.057144,"median":10.284523,"eighty":13.609447,"marketCap":23776806974.38},{"date":"2020-09-11","current":10.855043,"twenty":-8.057144,"median":10.291369,"eighty":13.600215,"marketCap":22417626544.05},{"date":"2020-09-18","current":11.337489,"twenty":-8.057144,"median":10.314383,"eighty":13.584791,"marketCap":23327291308.61},{"date":"2020-09-25","current":10.292189,"twenty":-8.057144,"median":10.319805,"eighty":13.561711,"marketCap":20378443894.99},{"date":"2020-10-02","current":10.238584,"twenty":-8.057144,"median":10.314383,"eighty":13.538631,"marketCap":20154725229.8},{"date":"2020-10-09","current":10.388678,"twenty":-8.057144,"median":10.308961,"eighty":13.478624,"marketCap":20836271816.86},{"date":"2020-10-16","current":10.077768,"twenty":-8.057144,"median":10.29616,"eighty":13.39092,"marketCap":20097076675.56},{"date":"2020-10-23","current":9.970558,"twenty":-8.057144,"median":10.291369,"eighty":13.344761,"marketCap":20240056139.58},{"date":"2020-10-30","current":13.354362,"twenty":-8.045382,"median":10.291779,"eighty":13.339443,"marketCap":19098996340.43},{"date":"2020-11-06","current":13.66753,"twenty":-8.027739,"median":10.300132,"eighty":13.478624,"marketCap":20189365488.02},{"date":"2020-11-13","current":14.912744,"twenty":-8.027739,"median":10.319805,"eighty":13.590618,"marketCap":22610846979.57},{"date":"2020-11-20","current":16.053569,"twenty":-8.027739,"median":10.344145,"eighty":13.620537,"marketCap":24261858653.1},{"date":"2020-11-27","current":16.19524,"twenty":-8.027739,"median":10.361737,"eighty":13.641085,"marketCap":24731503978.59},{"date":"2020-12-04","current":16.500951,"twenty":-8.027739,"median":10.372727,"eighty":13.68258,"marketCap":26223772364.1},{"date":"2020-12-11","current":17.224219,"twenty":-8.027739,"median":10.388678,"eighty":13.70689,"marketCap":27667442900.73},{"date":"2020-12-18","current":17.343521,"twenty":-8.027739,"median":10.399188,"eighty":13.778662,"marketCap":27962526123.89},{"date":"2020-12-24","current":17.052723,"twenty":-8.027739,"median":10.415218,"eighty":13.826153,"marketCap":26881415841.75},{"date":"2020-12-31","current":16.739555,"twenty":-8.027739,"median":10.428877,"eighty":13.864693,"marketCap":26994291439.99},{"date":"2021-01-08","current":17.887837,"twenty":-8.027739,"median":10.443632,"eighty":13.884097,"marketCap":28336383384.46},{"date":"2021-01-15","current":18.04442,"twenty":-8.004214,"median":10.45629,"eighty":13.94086,"marketCap":28718079297.45},{"date":"2021-01-22","current":17.5523,"twenty":-7.998333,"median":10.472905,"eighty":13.9633,"marketCap":27428996316},{"date":"2021-01-29","current":15.136435,"twenty":-7.998333,"median":10.484881,"eighty":13.996226,"marketCap":23416813550.86},{"date":"2021-02-05","current":16.068482,"twenty":-7.998333,"median":10.499343,"eighty":14.123084,"marketCap":25042104133.89},{"date":"2021-02-12","current":16.0312,"twenty":-7.998333,"median":10.512522,"eighty":14.180251,"marketCap":25204109478.1},{"date":"2021-02-19","current":16.143045,"twenty":-7.986571,"median":10.513852,"eighty":14.217179,"marketCap":25046465773.01},{"date":"2021-02-26","current":58.305857,"twenty":-7.968927,"median":10.548119,"eighty":14.277186,"marketCap":25507337685.76},{"date":"2021-03-05","current":62.192915,"twenty":-7.968927,"median":10.549134,"eighty":14.309498,"marketCap":27185340438.03},{"date":"2021-03-12","current":61.622813,"twenty":-7.968927,"median":10.55525,"eighty":14.383353,"marketCap":27404215357.16},{"date":"2021-03-19","current":61.415503,"twenty":-7.968927,"median":10.560215,"eighty":14.424897,"marketCap":27381860856.27},{"date":"2021-03-26","current":60.923143,"twenty":-7.968927,"median":10.566774,"eighty":14.471057,"marketCap":26275612062.35},{"date":"2021-04-01","current":61.311848,"twenty":-7.968927,"median":10.569887,"eighty":14.506881,"marketCap":26583440261.39},{"date":"2021-04-09","current":58.564995,"twenty":-7.963046,"median":10.584415,"eighty":14.560475,"marketCap":25527094664.96},{"date":"2021-04-16","current":59.627457,"twenty":-7.939522,"median":10.587425,"eighty":14.602488,"marketCap":26281880793.85},{"date":"2021-04-23","current":57.735756,"twenty":-7.939522,"median":10.608026,"eighty":14.657491,"marketCap":25100144058.23},{"date":"2021-04-30","current":57.269309,"twenty":-7.939522,"median":10.61798,"eighty":14.744064,"marketCap":24302726735.73},{"date":"2021-05-07","current":20.722698,"twenty":-7.939522,"median":10.625618,"eighty":14.842782,"marketCap":25005315360.88},{"date":"2021-05-14","current":21.619353,"twenty":-7.933641,"median":10.625618,"eighty":15.002221,"marketCap":26643921768.12},{"date":"2021-05-21","current":20.695527,"twenty":-7.904235,"median":10.640622,"eighty":15.167685,"marketCap":25157084391.01},{"date":"2021-05-28","current":20.025299,"twenty":-7.88071,"median":10.65789,"eighty":15.365348,"marketCap":24472773564.38},{"date":"2021-06-04","current":21.329525,"twenty":-7.88071,"median":10.669598,"eighty":15.402274,"marketCap":26866573068.16},{"date":"2021-06-11","current":21.655582,"twenty":-7.88071,"median":10.685426,"eighty":15.557539,"marketCap":27175480153.64},{"date":"2021-06-18","current":21.709924,"twenty":-7.88071,"median":10.704782,"eighty":15.583818,"marketCap":26245397627.8},{"date":"2021-06-25","current":25.088231,"twenty":-7.88071,"median":10.720006,"eighty":15.743857,"marketCap":30460069078.47},{"date":"2021-07-02","current":25.821858,"twenty":-7.851305,"median":10.727521,"eighty":15.919354,"marketCap":31007458421.16},{"date":"2021-07-09","current":25.006717,"twenty":-7.804255,"median":10.758908,"eighty":15.993918,"marketCap":29565641596.76},{"date":"2021-07-16","current":23.186235,"twenty":-7.792493,"median":10.78369,"eighty":16.056552,"marketCap":27597991192.03},{"date":"2021-07-23","current":23.104721,"twenty":1.744237,"median":10.795303,"eighty":16.096961,"marketCap":27080627944.38},{"date":"2021-07-30","current":23.847405,"twenty":4.224151,"median":10.801539,"eighty":16.246916,"marketCap":28048152007.56},{"date":"2021-08-06","current":12.710961,"twenty":4.403647,"median":10.812794,"eighty":16.246916,"marketCap":26445510448.34},{"date":"2021-08-13","current":12.905593,"twenty":4.442538,"median":10.823748,"eighty":16.240705,"marketCap":27744434941.12},{"date":"2021-08-20","current":12.656065,"twenty":4.657934,"median":10.823748,"eighty":16.204333,"marketCap":26967345402.64},{"date":"2021-08-27","current":13.274894,"twenty":4.807514,"median":10.828241,"eighty":16.153484,"marketCap":28519011180.03},{"date":"2021-09-03","current":13.15013,"twenty":5.094709,"median":10.857136,"eighty":16.096961,"marketCap":28507430734.94},{"date":"2021-09-10","current":12.740904,"twenty":5.313096,"median":10.873763,"eighty":16.08544,"marketCap":27364682362.77},{"date":"2021-09-17","current":12.805782,"twenty":5.45071,"median":10.889499,"eighty":16.079739,"marketCap":27601161170.58},{"date":"2021-09-24","current":12.725933,"twenty":5.492593,"median":10.924728,"eighty":16.071464,"marketCap":27244457816.11},{"date":"2021-10-01","current":13.818866,"twenty":5.504559,"median":10.92749,"eighty":16.059534,"marketCap":30101294872.59},{"date":"2021-10-08","current":14.512554,"twenty":5.540458,"median":10.942084,"eighty":16.040148,"marketCap":31766032985.79},{"date":"2021-10-15","current":14.772063,"twenty":5.636189,"median":10.962071,"eighty":16.008831,"marketCap":32297167497.92},{"date":"2021-10-22","current":14.422724,"twenty":5.69303,"median":10.9698,"eighty":15.993918,"marketCap":31388448015.98},{"date":"2021-10-29","current":14.208129,"twenty":5.707988,"median":10.982384,"eighty":15.993918,"marketCap":30938584888.05},{"date":"2021-11-05","current":14.357846,"twenty":5.731921,"median":11.005297,"eighty":15.971549,"marketCap":30508260850.86},{"date":"2021-11-12","current":10.821451,"twenty":5.779787,"median":10.996652,"eighty":15.934267,"marketCap":30028393272.71},{"date":"2021-11-19","current":10.078429,"twenty":5.80372,"median":10.978125,"eighty":15.919354,"marketCap":27735497042.93},{"date":"2021-11-26","current":9.663099,"twenty":5.815686,"median":10.9698,"eighty":15.901459,"marketCap":25946683687.22},{"date":"2021-12-03","current":10.139395,"twenty":5.833636,"median":10.962253,"eighty":15.859703,"marketCap":27663402839.39},{"date":"2021-12-10","current":10.314672,"twenty":5.833636,"median":10.946258,"eighty":15.825404,"marketCap":28555311336.09},{"date":"2021-12-17","current":10.078429,"twenty":5.845602,"median":10.937911,"eighty":15.782048,"marketCap":27314059035.32},{"date":"2021-12-23","current":10.097481,"twenty":5.872527,"median":10.92749,"eighty":15.71334,"marketCap":27258209523.55},{"date":"2021-12-31","current":10.249896,"twenty":5.911418,"median":10.917433,"eighty":15.590738,"marketCap":27187431472.42},{"date":"2022-01-07","current":10.101291,"twenty":5.926376,"median":10.889499,"eighty":15.588592,"marketCap":26932288402.65},{"date":"2022-01-14","current":10.672847,"twenty":5.941334,"median":10.873763,"eighty":15.587637,"marketCap":28758892730.03},{"date":"2022-01-21","current":10.863365,"twenty":5.9533,"median":10.875619,"eighty":15.583818,"marketCap":29601943576.06},{"date":"2022-01-28","current":10.996728,"twenty":6.102881,"median":10.889499,"eighty":15.583818,"marketCap":29787077559.89},{"date":"2022-02-04","current":11.053884,"twenty":6.177671,"median":10.911516,"eighty":15.557539,"marketCap":30226428284.35},{"date":"2022-02-11","current":11.32442,"twenty":6.204595,"median":10.924728,"eighty":15.557539,"marketCap":31213777266},{"date":"2022-02-18","current":11.419679,"twenty":6.264427,"median":10.942084,"eighty":15.557539,"marketCap":31437797276.81},{"date":"2022-02-25","current":11.674974,"twenty":6.719152,"median":10.966026,"eighty":15.557539,"marketCap":32235185643.05},{"date":"2022-03-04","current":8.775545,"twenty":7.060195,"median":10.9698,"eighty":15.557539,"marketCap":35993542030.87},{"date":"2022-03-11","current":8.93319,"twenty":7.246521,"median":10.9698,"eighty":15.557539,"marketCap":36596969016.47},{"date":"2022-03-18","current":8.591626,"twenty":7.364711,"median":10.9698,"eighty":15.557539,"marketCap":35253970222.95},{"date":"2022-03-25","current":9.432397,"twenty":7.512449,"median":10.9698,"eighty":15.557539,"marketCap":38980889412.18},{"date":"2022-04-01","current":9.274753,"twenty":7.608478,"median":10.9698,"eighty":15.557539,"marketCap":38450231073.35},{"date":"2022-04-08","current":9.379849,"twenty":7.682347,"median":10.9698,"eighty":15.557539,"marketCap":38840654118.15},{"date":"2022-04-14","current":8.79131,"twenty":7.734055,"median":10.9698,"eighty":15.557539,"marketCap":36814680340.58},{"date":"2022-04-22","current":8.814956,"twenty":7.848551,"median":10.9698,"eighty":15.557539,"marketCap":36083314330.36},{"date":"2022-04-29","current":8.423472,"twenty":7.937194,"median":10.9698,"eighty":15.557539,"marketCap":33232522355.71},{"date":"2022-05-06","current":8.612646,"twenty":8.036916,"median":10.9698,"eighty":15.557539,"marketCap":33355736677.76},{"date":"2022-05-13","current":6.665183,"twenty":8.103632,"median":10.9698,"eighty":15.557539,"marketCap":31053756069.43},{"date":"2022-05-20","current":6.100082,"twenty":8.103632,"median":10.9698,"eighty":15.557539,"marketCap":29215441427.83},{"date":"2022-05-27","current":6.443869,"twenty":8.103632,"median":10.9698,"eighty":15.557539,"marketCap":31633906458.52},{"date":"2022-06-03","current":7.09062,"twenty":8.103632,"median":10.9698,"eighty":15.557539,"marketCap":36015579040.45},{"date":"2022-06-10","current":6.768319,"twenty":8.103632,"median":10.9698,"eighty":15.557539,"marketCap":33175611750.38},{"date":"2022-06-17","current":5.930337,"twenty":8.103632,"median":10.9698,"eighty":15.557539,"marketCap":29053271209.52},{"date":"2022-06-24","current":4.596011,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":21309510065.4},{"date":"2022-07-01","current":5.049381,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":23031543041.38},{"date":"2022-07-08","current":4.941947,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":21588001138.43},{"date":"2022-07-15","current":4.507915,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":19716315930.61},{"date":"2022-07-22","current":4.426266,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":19171225427.54},{"date":"2022-07-29","current":4.898974,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":21883856364.26},{"date":"2022-08-05","current":3.574458,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":21338876009.71},{"date":"2022-08-12","current":3.730145,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":23041049912.2},{"date":"2022-08-19","current":3.601465,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":21140719616.75},{"date":"2022-08-26","current":3.841351,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":22629951917.79},{"date":"2022-09-02","current":3.650713,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":21012334466.97},{"date":"2022-09-09","current":3.704727,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":21967588896.88},{"date":"2022-09-16","current":3.65389,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":21341487133.73},{"date":"2022-09-23","current":3.23131,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":18854575930.98},{"date":"2022-09-30","current":3.294856,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":18534639915.46},{"date":"2022-10-07","current":3.717436,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":20860105711.81},{"date":"2022-10-14","current":3.431479,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":19210084039.28},{"date":"2022-10-21","current":3.738088,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":19779927748.93},{"date":"2022-10-28","current":3.828641,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":20554935737.41},{"date":"2022-11-04","current":4.035166,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":20491789367.72},{"date":"2022-11-11","current":3.24681,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":20458414210.6},{"date":"2022-11-18","current":3.361163,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":20337590990.79},{"date":"2022-11-25","current":3.344827,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":20723664325.37},{"date":"2022-12-02","current":3.127012,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":19844314857.84},{"date":"2022-12-09","current":2.988155,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":18750367698.78},{"date":"2022-12-16","current":2.903751,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":18284182498.81},{"date":"2022-12-23","current":3.131096,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":19947772061.04},{"date":"2022-12-30","current":3.294457,"twenty":8.121847,"median":10.9698,"eighty":15.557539,"marketCap":20529504239.87},{"date":"2023-01-06","current":3.602122,"twenty":7.977821,"median":10.962071,"eighty":15.448048,"marketCap":22389902276.09},{"date":"2023-01-13","current":3.694693,"twenty":7.915033,"median":10.92749,"eighty":15.353601,"marketCap":23782172411.38},{"date":"2023-01-20","current":3.74234,"twenty":7.848551,"median":10.9129,"eighty":15.15206,"marketCap":24396148087.2},{"date":"2023-01-27","current":3.549029,"twenty":7.730361,"median":10.871907,"eighty":14.912744,"marketCap":23576646443.82},{"date":"2023-02-03","current":3.453735,"twenty":7.67496,"median":10.855043,"eighty":14.784787,"marketCap":22203715289.17},{"date":"2023-02-10","current":3.578979,"twenty":7.608478,"median":10.823748,"eighty":14.726178,"marketCap":22573097153.72},{"date":"2023-02-17","current":3.452374,"twenty":7.460741,"median":10.819131,"eighty":14.657544,"marketCap":21286938129.56},{"date":"2023-02-24","current":3.566727,"twenty":7.361018,"median":10.801539,"eighty":14.626454,"marketCap":22170808225.69},{"date":"2023-03-03","current":3.545128,"twenty":7.216974,"median":10.78369,"eighty":14.586838,"marketCap":23427703717.77},{"date":"2023-03-10","current":3.317459,"twenty":7.088595,"median":10.7295,"eighty":14.524941,"marketCap":22187614317.96},{"date":"2023-03-17","current":3.122315,"twenty":7.0094,"median":10.713578,"eighty":14.500509,"marketCap":20406573454.93},{"date":"2023-03-24","current":2.988315,"twenty":6.781898,"median":10.678394,"eighty":14.458692,"marketCap":19971462825.74},{"date":"2023-03-31","current":3.187363,"twenty":6.671286,"median":10.65789,"eighty":14.423159,"marketCap":21760504177.85},{"date":"2023-04-06","current":3.30445,"twenty":6.650793,"median":10.635059,"eighty":14.418662,"marketCap":22872624729},{"date":"2023-04-14","current":3.334372,"twenty":6.418945,"median":10.625618,"eighty":14.355658,"marketCap":23842101468.43},{"date":"2023-04-21","current":3.27843,"twenty":6.252461,"median":10.590434,"eighty":14.307221,"marketCap":22859238559.53},{"date":"2023-04-28","current":2.84651,"twenty":6.208833,"median":10.584415,"eighty":14.251173,"marketCap":19349032795.29},{"date":"2023-05-05","current":2.588919,"twenty":6.139878,"median":10.566774,"eighty":14.215464,"marketCap":17727705001.21},{"date":"2023-05-12","current":2.799899,"twenty":5.947317,"median":10.55525,"eighty":14.180251,"marketCap":18718310549.59},{"date":"2023-05-19","current":2.830711,"twenty":5.851586,"median":10.547103,"eighty":14.107762,"marketCap":19231782153.84},{"date":"2023-05-26","current":2.794541,"twenty":5.779787,"median":10.513852,"eighty":14.036335,"marketCap":19186073980.7},{"date":"2023-06-02","current":2.765068,"twenty":5.636189,"median":10.502473,"eighty":13.996226,"marketCap":19252463212.38},{"date":"2023-06-09","current":2.908412,"twenty":5.338256,"median":10.484881,"eighty":13.941499,"marketCap":21397594307.35},{"date":"2023-06-16","current":2.884224,"twenty":4.96902,"median":10.443632,"eighty":13.927233,"marketCap":21241570166.18},{"date":"2023-06-23","current":2.877526,"twenty":4.924758,"median":10.424038,"eighty":13.931562,"marketCap":21499710361.53},{"date":"2023-06-30","current":2.884224,"twenty":4.886941,"median":10.390367,"eighty":13.91118,"marketCap":21130530306.86},{"date":"2023-07-07","current":2.853413,"twenty":4.835802,"median":10.372727,"eighty":13.879481,"marketCap":20797568199.88},{"date":"2023-07-14","current":2.995414,"twenty":4.714842,"median":10.361737,"eighty":13.869409,"marketCap":22415987059.75},{"date":"2023-07-21","current":2.921734,"twenty":4.596011,"median":10.322954,"eighty":13.870981,"marketCap":22516260606.85},{"date":"2023-07-28","current":2.945847,"twenty":4.507915,"median":10.29616,"eighty":13.863121,"marketCap":23012958238.52},{"date":"2023-08-04","current":3.121339,"twenty":4.248084,"median":10.286261,"eighty":13.696764,"marketCap":23184235668.09},{"date":"2023-08-11","current":3.839397,"twenty":4.000076,"median":10.267916,"eighty":13.604343,"marketCap":23607572072.62},{"date":"2023-08-18","current":3.885026,"twenty":3.90194,"median":10.240429,"eighty":13.50446,"marketCap":23091698704.87},{"date":"2023-08-25","current":3.896866,"twenty":3.896866,"median":10.224768,"eighty":13.50446,"marketCap":23283897302.7},{"date":"2023-09-01","current":3.986507,"twenty":3.896866,"median":10.181829,"eighty":13.50446,"marketCap":23647467030.48},{"date":"2023-09-08","current":4.033865,"twenty":3.896866,"median":10.143425,"eighty":13.50446,"marketCap":24250288549.3},{"date":"2023-09-15","current":4.15395,"twenty":3.896866,"median":10.123411,"eighty":13.354362,"marketCap":25668539731.74},{"date":"2023-09-22","current":4.174247,"twenty":3.896866,"median":10.099573,"eighty":13.274894,"marketCap":25723339627.09},{"date":"2023-09-29","current":3.945915,"twenty":3.896866,"median":10.078098,"eighty":13.15013,"marketCap":23472544770.05},{"date":"2023-10-06","current":3.925618,"twenty":3.896866,"median":10.071608,"eighty":13.050319,"marketCap":21839950653.49},{"date":"2023-10-12","current":4.240209,"twenty":3.896866,"median":10.039952,"eighty":12.940527,"marketCap":24300899049.42},{"date":"2023-10-20","current":4.42964,"twenty":3.89593,"median":9.98317,"eighty":12.884329,"marketCap":25310163915.08},{"date":"2023-10-27","current":4.186086,"twenty":3.893123,"median":9.960618,"eighty":12.82556,"marketCap":24462456576.38},{"date":"2023-11-03","current":4.194543,"twenty":3.893123,"median":9.927672,"eighty":12.803786,"marketCap":25266844123.99},{"date":"2023-11-10","current":4.85945,"twenty":3.893123,"median":9.909277,"eighty":12.803786,"marketCap":23963749044.29},{"date":"2023-11-17","current":4.952503,"twenty":3.893123,"median":9.902932,"eighty":12.803786,"marketCap":24118759651.85},{"date":"2023-11-24","current":5.169817,"twenty":3.893123,"median":9.891721,"eighty":12.803786,"marketCap":25265887504.92},{"date":"2023-12-01","current":5.211175,"twenty":3.893123,"median":9.879822,"eighty":12.803786,"marketCap":25611546029.96},{"date":"2023-12-08","current":5.097439,"twenty":3.894059,"median":9.834565,"eighty":12.801789,"marketCap":25297686803.83},{"date":"2023-12-15","current":5.283553,"twenty":3.894059,"median":9.834565,"eighty":12.801789,"marketCap":26543991442.74},{"date":"2023-12-22","current":4.869967,"twenty":3.894059,"median":9.834565,"eighty":12.801789,"marketCap":24577966848.99},{"date":"2023-12-29","current":4.838949,"twenty":3.893123,"median":9.836153,"eighty":12.803786,"marketCap":25178756823.67},{"date":"2024-01-05","current":4.973364,"twenty":3.892187,"median":9.837742,"eighty":12.805782,"marketCap":25160462757.48},{"date":"2024-01-12","current":4.869967,"twenty":3.892187,"median":9.837742,"eighty":12.805782,"marketCap":24641765108.78},{"date":"2024-01-19","current":4.756231,"twenty":3.892187,"median":9.844654,"eighty":12.807778,"marketCap":24078522670.15},{"date":"2024-01-26","current":4.869967,"twenty":3.892187,"median":9.837742,"eighty":12.805782,"marketCap":24572977032.09},{"date":"2024-02-02","current":4.849288,"twenty":3.892187,"median":9.837742,"eighty":12.805782,"marketCap":24830968078.3},{"date":"2024-02-09","current":4.838949,"twenty":3.892187,"median":9.837742,"eighty":12.805782,"marketCap":24362672332.27},{"date":"2024-02-16","current":4.745892,"twenty":3.892187,"median":9.837742,"eighty":12.805782,"marketCap":24147298816.1},{"date":"2024-02-23","current":4.838949,"twenty":3.892187,"median":9.834565,"eighty":12.805782,"marketCap":24431341401.84},{"date":"2024-03-01","current":4.939525,"twenty":3.893123,"median":9.737218,"eighty":12.803786,"marketCap":23952488130.27},{"date":"2024-03-08","current":4.508126,"twenty":3.893123,"median":9.70238,"eighty":12.803786,"marketCap":21947666113.83},{"date":"2024-03-15","current":4.572814,"twenty":3.893123,"median":9.667099,"eighty":12.803786,"marketCap":22370689783.86},{"date":"2024-03-22","current":4.583599,"twenty":3.893123,"median":9.548009,"eighty":12.778323,"marketCap":22474207427.59},{"date":"2024-03-28","current":4.475749,"twenty":3.893123,"median":9.466237,"eighty":12.778323,"marketCap":22089724123.39},{"date":"2024-04-05","current":5.004211,"twenty":3.892187,"median":9.402489,"eighty":12.787678,"marketCap":25269737391.93},{"date":"2024-04-12","current":4.874792,"twenty":3.892187,"median":9.295772,"eighty":12.787678,"marketCap":24296961694.18},{"date":"2024-04-19","current":4.799298,"twenty":3.892187,"median":9.274753,"eighty":12.787678,"marketCap":23301659582.09},{"date":"2024-04-26","current":4.971857,"twenty":3.893123,"median":9.175126,"eighty":12.778323,"marketCap":23960050881.17},{"date":"2024-05-03","current":4.864007,"twenty":3.893123,"median":8.95412,"eighty":12.778323,"marketCap":23752567318.04},{"date":"2024-05-10","current":5.383345,"twenty":3.893123,"median":8.867182,"eighty":12.778323,"marketCap":24064602087.79},{"date":"2024-05-17","current":5.430568,"twenty":3.893123,"median":8.795251,"eighty":12.778323,"marketCap":24652224339.04},{"date":"2024-05-24","current":5.418762,"twenty":3.893123,"median":8.740075,"eighty":12.778323,"marketCap":24601197777.08},{"date":"2024-05-31","current":5.548903,"twenty":3.893123,"median":8.682856,"eighty":12.778323,"marketCap":24948806455.5},{"date":"2024-06-07","current":5.584322,"twenty":3.893123,"median":8.59294,"eighty":12.778323,"marketCap":24693614094.28},{"date":"2024-06-14","current":5.678771,"twenty":3.892187,"median":8.439501,"eighty":12.787678,"marketCap":23998459101.92},{"date":"2024-06-21","current":5.501679,"twenty":3.892187,"median":8.381434,"eighty":12.789302,"marketCap":22878611698.83},{"date":"2024-06-28","current":5.489873,"twenty":3.892187,"median":8.310231,"eighty":12.794176,"marketCap":22954501069.55},{"date":"2024-07-05","current":5.383617,"twenty":3.892187,"median":8.217895,"eighty":12.794176,"marketCap":22901200413.63},{"date":"2024-07-12","current":5.289168,"twenty":3.892187,"median":8.13183,"eighty":12.794176,"marketCap":23204604596.91},{"date":"2024-07-15","current":5.171106,"twenty":3.892187,"median":8.107092,"eighty":12.794176,"marketCap":22824658784.59},{"date":"2024-08-02","current":5.005819,"twenty":3.876246,"median":7.931653,"eighty":12.819755,"marketCap":21485677284.4},{"date":"2024-08-09","current":4.923176,"twenty":3.876246,"median":7.848551,"eighty":12.819755,"marketCap":20886419400.33},{"date":"2024-08-16","current":5.133096,"twenty":3.876246,"median":7.728514,"eighty":12.819755,"marketCap":21386096998.62},{"date":"2024-08-23","current":5.009826,"twenty":3.876246,"median":7.673113,"eighty":12.819755,"marketCap":20566937957.91},{"date":"2024-08-30","current":5.034444,"twenty":3.876246,"median":7.608478,"eighty":12.819755,"marketCap":20378972525.7},{"date":"2024-09-06","current":4.739024,"twenty":3.876246,"median":7.506908,"eighty":12.819755,"marketCap":18940304213.61},{"date":"2024-09-13","current":4.751333,"twenty":3.876246,"median":7.359171,"eighty":12.819755,"marketCap":18705266064.42},{"date":"2024-09-20","current":4.689788,"twenty":3.876246,"median":7.2022,"eighty":12.819755,"marketCap":18729179929.81},{"date":"2024-09-27","current":4.677478,"twenty":3.876246,"median":7.088216,"eighty":12.819755,"marketCap":18693431578.81},{"date":"2024-10-04","current":4.689788,"twenty":3.876246,"median":7.005747,"eighty":12.819755,"marketCap":18661799148.11},{"date":"2024-10-11","current":4.542078,"twenty":3.876246,"median":6.779635,"eighty":12.819755,"marketCap":17972116015.88},{"date":"2024-10-18","current":4.283586,"twenty":3.876246,"median":6.671286,"eighty":12.819755,"marketCap":16817039340.09},{"date":"2024-10-25","current":4.258967,"twenty":3.876246,"median":6.623283,"eighty":12.819755,"marketCap":16507746997.84},{"date":"2024-10-31","current":4.234349,"twenty":3.876246,"median":6.412714,"eighty":12.819755,"marketCap":16032080809.48},{"date":"2024-11-08","current":4.086639,"twenty":3.871856,"median":6.252461,"eighty":12.821752,"marketCap":15687984275.04},{"date":"2024-11-15","current":4.646307,"twenty":3.871856,"median":6.207587,"eighty":12.821752,"marketCap":15845911157.34},{"date":"2024-11-22","current":4.84832,"twenty":3.871856,"median":6.102881,"eighty":12.821752,"marketCap":16898815061.19},{"date":"2024-11-29","current":4.794465,"twenty":3.871856,"median":5.9533,"eighty":12.821752,"marketCap":16560180234.91},{"date":"2024-12-06","current":4.76753,"twenty":3.871856,"median":5.863552,"eighty":12.821752,"marketCap":16531483452.13},{"date":"2024-12-13","current":4.888738,"twenty":3.871856,"median":5.80372,"eighty":12.821752,"marketCap":17216536903.6},{"date":"2024-12-20","current":4.525113,"twenty":3.871856,"median":5.699013,"eighty":12.821752,"marketCap":15739882212.82},{"date":"2024-12-27","current":4.471243,"twenty":3.871856,"median":5.666965,"eighty":12.821752,"marketCap":15580193842.54},{"date":"2025-01-03","current":4.834868,"twenty":3.871856,"median":5.596128,"eighty":12.821752,"marketCap":16773742492.85},{"date":"2025-01-10","current":4.888738,"twenty":3.867466,"median":5.572516,"eighty":12.823748,"marketCap":17240401252.68},{"date":"2025-01-17","current":5.036882,"twenty":3.867466,"median":5.525012,"eighty":12.823748,"marketCap":17692127998.87},{"date":"2025-01-24","current":4.780998,"twenty":3.867466,"median":5.495776,"eighty":12.823748,"marketCap":17203435182.51},{"date":"2025-01-31","current":5.454377,"twenty":3.867466,"median":5.476216,"eighty":12.823748,"marketCap":19996471191.52},{"date":"2025-02-07","current":5.387039,"twenty":3.867466,"median":5.430705,"eighty":12.823748,"marketCap":19814319642.43},{"date":"2025-02-14","current":5.642924,"twenty":3.867466,"median":5.419036,"eighty":12.823748,"marketCap":20806134000.52},{"date":"2025-02-21","current":6.020017,"twenty":3.867466,"median":5.419036,"eighty":12.823748,"marketCap":22526244057.4},{"date":"2025-02-28","current":5.521715,"twenty":3.867466,"median":5.419036,"eighty":12.823748,"marketCap":20445151021.05},{"date":"2025-03-07","current":5.506086,"twenty":3.863076,"median":5.395151,"eighty":12.825744,"marketCap":20009097615.46},{"date":"2025-03-14","current":5.533616,"twenty":3.863076,"median":5.395151,"eighty":12.825744,"marketCap":20124812820.07},{"date":"2025-03-21","current":5.781504,"twenty":3.863076,"median":5.430568,"eighty":12.825744,"marketCap":20608888189.85},{"date":"2025-03-28","current":5.987986,"twenty":3.863076,"median":5.451025,"eighty":12.825744,"marketCap":21549111072.47},{"date":"2025-04-02","current":5.740208,"twenty":3.863076,"median":5.451025,"eighty":12.825744,"marketCap":20657921498.99}],"updateTime":1743746054893}}}